Hollow three-dimensional unit of retinal tissue and its use in the treatment of retinopathy
Patent Information
- Application Number
- DE602020041706
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-08-12
- Filing Date
- 2020-08-12
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2040-08-12
AI Technical Summary
Current treatments for retinal diseases, such as age-related macular degeneration and retinopathy, face challenges including ineffective drug injections, invasive surgeries, and poor cell differentiation and integration of retinal implants, leading to limited success and significant side effects.
Development of hollow three-dimensional retinal tissue units comprising differentiated living human retinal pigment epithelium cells with their basal faces oriented outwards, integrated with an extracellular matrix, allowing correct polarization and minimally invasive implantation at Bruch's membrane, reducing the need for complex surgeries and improving cell survival and functionality.
The solution enables effective, lasting integration and survival of retinal cells, reducing the risk of retinal detachment and hemorrhage, while allowing for easier and less invasive surgical procedures, potentially improving vision in patients with degenerative retinal diseases.
Description
Technical field
[0001] The present invention relates to the treatment of retinal diseases, in particular by the use of specific tissue units comprising at least one retinal pigment epithelium. The invention also relates to a method for preparing these tissue units as well as kits for implanting these tissue units in the eye to perform grafts of all or part of the retina. Prior art
[0002] Retinal diseases, or retinopathies, are one of the leading causes of vision loss worldwide. The retina, which lines the back of the eye, is made up of pigment epithelial cells and nerve cells that receive light. These nerve cells translate light into electrical signals that travel to the brain via the optic nerve. When retinal cells, particularly those of the retinal pigment epithelium, degenerate or malfunction, blind areas of the visual field appear.
[0003] Retinopathies can have various origins: they can be linked to aging, such as age-related macular degeneration (AMD), be hereditary, such as pigmentary retinopathy or retinal dystrophy, be linked to trauma such as solar retinopathy, or derive from another pathology, such as diabetic retinopathy or hypertensive retinopathy.
[0004] AMD is the leading cause of visual impairment in older adults. This condition is caused by damage to the macula, the central area of the retina, which transmits most of the visual information to the brain. It results in the appearance of a blind spot in the center of the visual field. AMD can present in two forms: a dry or atrophic form: it is characterized by the progressive disappearance of cells in the macula. It therefore develops slowly and constitutes the most frequent form of AMD; a wet or exudative form: it is characterized by the formation of abnormal blood vessels under the retina which lead in particular to its detachment.
[0005] There is currently no treatment for the dry form of AMD. The only treatment is to delay it by taking dietary supplements (vitamins C, E, and antioxidant minerals). For several years now, for wet AMD, if the disease is not too advanced, an injection into the eye of a drug that blocks the proliferation of blood vessels can improve the disease, but this treatment requires monthly injections and does not provide entirely satisfactory results.
[0006] Retinopathy pigmentosa is a genetic disease that can be hereditary. It is characterized by degeneration of retinal cells linked to the mutation of one or more genes. The disease progresses slowly, leading to blindness, and there is currently no treatment.
[0007] Diabetic retinopathy is a retinal disorder that occurs in the context of diabetes. It is linked to excessive sugar concentration in the small blood vessels of the retina, which leads to their degradation. The lack of oxygen supply induces the formation of new, more fragile blood vessels. Their rupture and the resulting microhemorrhages can lead to retinal detachment. As with the wet form of AMD, it is possible to administer injections of anti-angiogenic drugs, but this treatment is poorly effective. Laser treatment can also be used to burn away abnormal vessels, but its effectiveness is limited.
[0008] Recently, new therapeutic approaches have been described for the treatment of retinal diseases.
[0009] Recent therapeutic trials have explored the possibility of placing a retinal implant (artificial retina) but the resolution of this implant remains low.
[0010] Cell therapy trials have also been conducted with the aim of replacing retinal cells that have degenerated with stem cells capable of differentiating into retinal epithelial, neural or vascular cells (hRPCs or "human retinal progenitor cells"). However, no trial has been conclusive to date, in particular, cell differentiation after implantation is not controlled and the intravitreal injection, which is the route of administration tested, does not correspond to a physiological mechanism, which has led to undesirable side effects. (https: / / clinicaltrials.gov / ct2 / show / results / NCT02320812).Moreover, these progenitor cells exist in vivo in humans without allowing regeneration of the adult retina (Tang et al. “Progress of stem / progenitor cell-based therapy for retinal degeneration” Journal of Translational Medicine, May 10, 2017).
[0011] Furthermore, membranes or sheets of retinal cells for use as implants have been described. This is the case of application US20160310637 or application EP2570139 which disclose membranes or sheets of retinal cells obtained from retinal cells taken from humans and cultured, said membranes or sheets being intended to be implanted in the eye. However, this technology is not satisfactory because it requires producing a very large number of cells compared to the number of grafted cells (8 batches produced to allow quality controls and the majority of cells in each batch are not positioned on the implant), in addition, the implantation requires performing a long and complex surgery requiring specific grafting expertise for the practitioner and very invasive for the patient.
[0012] Application EP3211071 also describes retinal tissues in the form of suspended aggregates obtained from pluripotent stem cells. The suspension is then injected into the eye. This solution is also not satisfactory because the injection does not allow for the preservation of a functional structure (in particular a functional polarization): i) in the case of the pigment epithelium, the apical face of the cells must be presented opposite the external segments of the photoreceptors of the graft, limiting the survival and functionality of the graft ii) in the case of the photoreceptors, the external segment must be positioned towards the outside of the eye opposite the cells of the pigment epithelium and the synaptic terminal must face the center of the eye to connect the rest of the neural retina).Furthermore, this technique requires the injection of a large volume of liquid into the eye, and leads, as with all other prior art solutions, to a significant retinal detachment, over an area larger than the area to be treated with the risk of causing local hemorrhages during the incision or injection. Current solutions also require three or four incisions to be made as described in Zarbin et al. (“Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration” Stem Cells Translational Medicine, 2019;8:466-477). WO 2017 / 176810 describes a three-dimensional retinal tissue unit comprising a concentric laminar structure comprising a center of retinal pigment epithelium cells, a layer of RGCs, a layer of second-order retinal neurons, a layer of photoreceptors and a layer of retinal pigment epithelium cells as well as a hydrogel.
[0013] The objective of the invention is to overcome these various problems of the prior art, and to propose a solution for the easy, rapid and minimally invasive implantation of correctly polarized retinal cells, and their integration into the host organ, so as to permanently and reliably replace the retinal cells that have degenerated in patients suffering from degenerative pathologies of the retina. Summary of the invention
[0014] According to the invention, the effectiveness of retinal tissue grafting largely depends on the correct in situ incorporation (in particular correct apico-basal polarization) of the graft via the adhesion of the basal face of the retinal pigment epithelium cells at the Bruch membrane. Therefore, to meet the objective of the invention, the inventors have developed particular hollow three-dimensional cellular networks comprising at least one layer of differentiated living human retinal pigment epithelium cells, organized around a lumen, said retinal pigment epithelium cells having their basal faces oriented outwards. This tissue unit preferably also comprises an outer layer of extracellular matrix at the basal face of the retinal pigment epithelium cells promoting the integration and survival of the cells, once injected into the eye.The tissue unit according to the invention may also contain other retinal cells, organized in the form of one or more layers within the retinal pigment epithelium cell layer, in the inner lumen, i.e. at the apical face of the retinal pigment epithelium cells. These other cells preferably form all or part of a retinal neural tissue.
[0015] The invention therefore relates to a hollow three-dimensional tissue unit, comprising, organized around an internal lumen, at least one layer of differentiated living human retinal pigment epithelium cells, the basal face of each retinal pigment epithelium cell of which is positioned towards the outside and the apical face towards the internal lumen. The tissue unit according to the invention is preferably in the form of a hollow ovoid, a hollow cylinder, a hollow spheroid or a hollow sphere, or a section of these elements along a plane.
[0016] The invention also relates to such a hollow three-dimensional tissue unit for use in the treatment of retinal diseases, in particular by implantation in the eye, at the level of Bruch's membrane.
[0017] Advantageously, since the graft is performed with retinal tissue units according to the invention, organized and of submillimeter size, the intervention does not require the precise positioning of a single graft as in the prior art. This limits the need for (potentially traumatic) retinal detachment and consequently also the intensity of drainage of the vitreous humor from the eye. In addition, the invention has the advantage of being able to limit the surgical intervention to a single incision of the eye compared to three to four today.
[0018] In addition, the polarization of the retinal pigment epithelium layer (basal face towards the outside and the apical face towards the inner light) allows the retinal tissue units to position themselves correctly when they are grafted into the eye and to ensure the success of the graft. Indeed, thanks to the positioning of their basal face on the outside, the retinal tissue units according to the invention attach to the extracellular matrix of the back of the eye (Brusch membrane) by emitting cells adherent to the substrate which migrate and form a monolayer.
[0019] The invention also relates to a method for preparing a hollow three-dimensional retinal tissue unit comprising the steps of: producing a cellular microcompartment comprising, inside a hydrogel capsule: * retinal pigment epithelium cells and optionally other retinal cells, or * cells capable of differentiating into retinal pigment epithelium cells and optionally other retinal cells, the cells capable of differentiating at least into retinal pigment epithelium cells being chosen from: * stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, * progenitor cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, * differentiated cells capable of undergoing trans-differentiation into retinal cells, at least into retinal pigment epithelium cells,* differentiated cells capable of undergoing reprogramming so that they become induced pluripotent stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells. if the microcompartment comprises cells capable of differentiating into retinal pigment epithelium cells and possibly into other retinal cells: inducing cell differentiation within the cell microcompartment, so as to obtain retinal pigment epithelium cells and possibly other retinal cells, removing the hydrogel capsules by hydrolysis, dissolution, piercing and / or rupture to recover the retinal pigment epithelium cells and any other retinal cells as a tissue unit.
[0020] Finally, the invention also relates to a kit for implanting hollow three-dimensional tissue units in the eye comprising at least: between 1 and 10,000 tissue units, optionally encapsulated in hydrogel capsules, and a surgical implantation device capable of implanting said tissue unit(s) into a human eye. Brief description of the Figures
[0021] Figure 1 : there figure 1 is a schematic representation of a sectional view of a tissue unit 10 according to the invention, with a retinal pigment epithelium layer 12 and an inner lumen 14, A corresponding to the apical face of the retinal pigment epithelium cells and B corresponding to the basal face of the retinal pigment epithelium cells. Figure 2 : there figure 2is a schematic representation of a sectional view of a tissue unit 10 according to the invention, with a retinal pigment epithelium layer 12, a lumen 14 and an extracellular matrix layer 16, A corresponding to the apical face of the retinal pigment epithelium cells and B corresponding to the basal face of the retinal pigment epithelium cells. Figure 3 : there figure 3 is a schematic representation of a sectional view of a microcompartment 20 comprising a hydrogel capsule 22 and a tissue unit 10 according to the invention, the tissue unit 10 being constituted by a layer of pigment epithelium 12, a lumen 14 and a layer of extracellular matrix 16, A corresponding to the apical face of the retinal pigment epithelium cells and B corresponding to the basal face of the retinal pigment epithelium cells. Figure 4 : there figure 4is a schematic representation of a cross-sectional view of a microcompartment 20 comprising a hydrogel capsule 22 and a tissue unit 10 according to the invention, the tissue unit 10 being constituted by a layer of extracellular matrix 16, a layer of retinal pigment epithelium 12, a layer of retinal cells other than retinal pigment epithelium cells 18, and a lumen 14, A corresponding to the apical face of the retinal pigment epithelium cells and B corresponding to the basal face of the retinal pigment epithelium cells. Figure 5 : there Figure 5 represents a microscopy image of a hydrogel (alginate) microcompartment encapsulating a tissue unit according to the invention. Figure 6 : there figure 6 represents microscopy images of hydrogel (alginate) microcompartments encapsulating a small tissue unit according to the invention (A) and a large tissue unit according to the invention (B). Figure 7 : there figure 7represents microscopy images of hydrogel (alginate) microcompartments encapsulating one or more tissue units according to the invention with different cell densities. Figure 8 : there figure 8 represents retinal tissue units according to the invention, without hydrogel capsule, on a substrate simulating the extracellular matrix of the back of the eye (here matrigel simulating Brusch's membrane) at different times until formation of a monolayer of retinal pigment epithelium. Figure 9 : there figure 9 represents microscopy images and a graph that show that cell polarization can be achieved by deposition of a matrix layer on the inner face of alginate capsules. Detailed description of the invention Definitions
[0022] For the purposes of the invention, the term "alginate" means linear polysaccharides formed from β-D-mannuronate and α-L-guluronate, salts and derivatives thereof.
[0023] For the purposes of the invention, the term “hydrogel capsule” means a three-dimensional structure formed from a matrix of polymer chains, swollen by a liquid and preferably water.
[0024] For the purposes of the invention, the term "human cells" means human cells or immunologically humanized non-human mammalian cells. Even when not specified, the cells, stem cells, progenitor cells and tissues according to the invention consist of or are obtained from human cells or from immunologically humanized non-human mammalian cells.
[0025] For the purposes of the invention, the term “progenitor cell” means a stem cell already engaged in cellular differentiation into retinal cells but not yet differentiated.
[0026] For the purposes of the invention, the term "embryonic stem cell" means a pluripotent stem cell derived from the inner cell mass of the blastocyst. The pluripotency of embryonic stem cells can be assessed by the presence of markers such as the transcription factors OCT4 and NANOG and surface markers such as SSEA3 / 4, Tra-1-60 and Tra-1-81. The embryonic stem cells according to the invention are obtained without destroying the embryo from which they originate, for example using the technique described in Chang et al. (Cell Stem Cell, 2008, 2(2)): 113-117). Optionally, embryonic stem cells of human beings can be excluded.
[0027] For the purposes of the invention, the term "pluripotent stem cell" or "pluripotent cell" means a cell that has the capacity to form all the tissues present in the entire original organism, without being able to form an entire organism as such. These may in particular be induced pluripotent stem cells, embryonic stem cells or MUSE cells (for "Multilineage-differentiating Stress Enduring"). For the purposes of the invention, the term "induced pluripotent stem cell" means a pluripotent stem cell induced to pluripotency by genetic reprogramming of differentiated somatic cells. These cells are in particular positive for pluripotency markers, such as alkaline phosphatase staining and the expression of the proteins NANOG, SOX2, OCT4 and SSEA3 / 4. Examples of methods for obtaining induced pluripotent stem cells are described in the articles Yu et al.(Science 2007, 318 (5858): 1917-1920), Takahashi et al (Cell, 207, 131(5): 861-872) and Nakagawa et al (Nat Biotechnol, 2008, 26(1): 101-106).
[0028] For the purposes of the invention, “differentiated” cells are understood to mean cells which have a particular phenotype, as opposed to pluripotent stem cells which are not differentiated.
[0029] By "Feret diameter" of a unit of tissue is meant the distance "d" between two tangents to said unit of tissue, these two tangents being parallel, such that the entire projection of the unit of tissue is between these two parallel tangents.
[0030] By "implantation" or "graft" in the eye within the meaning of the invention, we mean the action of depositing in the eye at a particular location, at least one unit of tissue according to the invention. The implantation can be carried out by any means, in particular by injection.
[0031] For the purposes of the invention, the term “largest dimension” of a unit of tissue means the value of the largest Feret diameter of said unit of tissue.
[0032] For the purposes of the invention, the term “smallest dimension” of a unit of tissue means the value of the smallest Feret diameter of said unit of tissue.
[0033] By "tissue unit" or "retinal tissue unit" according to the invention is meant a unit comprising at least one retinal tissue. The retinal tissue unit may comprise several retinal tissues assembled together with a functional structure. The tissue unit according to the invention comprises at least one retinal pigment epithelial tissue and it may also contain another retinal tissue, in particular a retinal neural or retinal vascular tissue and / or at least one other constituent such as, for example, an extracellular matrix. Fabric unit
[0034] The invention therefore relates to a three-dimensional retinal tissue unit.
[0035] The tissue unit according to the invention is hollow. It always comprises an internal light or lumen which constitutes the hollow part of the tissue unit. This light is generated at the time of the formation of the tissue unit by the retinal cells which multiply and develop. The lumen contains a liquid, in particular a culture medium (such as a medium based on DMEM or DMEM-F12 and / or Neurobasal and supplemented with B27 or N-2 or NS21) and / or a liquid secreted by the cells of the tissue unit. Advantageously, the presence of this hollow part in the retinal tissue unit allows better integration at the level of the retina when it is implanted in the eye.
[0036] The tissue unit according to the invention comprises at least one layer of retinal pigment epithelium cells. These cells are human cells, living and differentiated into retinal pigment epithelium cells. The layer of retinal epithelium cells is organized around the inner lumen. The cells constituting this layer together form a retinal pigment epithelium, and their basal faces are all positioned towards the outside of the cell unit, and their apical faces are all positioned towards the inside, i.e. towards the inner lumen. Preferably, the juxtaposed cells are linked together on their lateral faces by tight junctions.
[0037] According to a particularly suitable embodiment, the tissue unit according to the invention also comprises an outer layer of extracellular matrix. This outer layer of extracellular matrix is located at the basal face of the retinal pigment epithelium cells. The cellular matrix layer may consist of cellular matrix secreted by retinal pigment epithelium cells and / or of extracellular matrix added at the time of preparation of the cell unit.
[0038] The extracellular matrix layer may form a gel. It comprises a mixture of proteins and extracellular compounds necessary for the culture of retinal pigment epithelium cells. Preferably, the extracellular matrix comprises structural proteins, such as collagen, laminins, entactin, vitronectin, as well as growth factors, such as TGF-beta and / or EGF. The extracellular matrix layer may consist of or comprise Matrigel ®< and / or Geltrex ®< and / or a hydrogel-type matrix of plant origin such as modified alginates or of synthetic origin or of copolymer of poly(N-isopropylacrylamide) and poly(ethylene glycol) (PNIPAAm-PEG) type Mebiol ®< .
[0039] At the surface of the extracellular matrix layer in contact with the retinal pigment epithelium layer, the extracellular matrix may possibly contain one or more retinal pigment epithelium cells.
[0040] When the extracellular matrix is present, advantageously the retinal cells organized in three dimensions around the internal lumen, already interact with an extracellular matrix, which facilitates their implantation at the level of the retina.
[0041] The tissue unit according to the invention may comprise one or more other layers of retinal cells other than retinal pigment epithelium cells. These cells are human cells, which are alive and differentiated into retinal cells other than retinal pigment epithelium cells. The layer(s) of retinal cells other than retinal pigment epithelium cells are arranged within the layer of retinal epithelium cells, i.e. at the apical face of the retinal pigment epithelium cells, organized around the lumen.
[0042] In one embodiment, the retinal cells other than retinal pigment epithelium cells are selected from rods, cones, ganglion cells, amacrine cells, bipolar cells, and horizontal cells.
[0043] When the cellular unit comprises at least two layers of retinal cells other than retinal pigment epithelium cells, the different layers are organized successively around the inner lumen.
[0044] Preferably, the tissue unit according to the invention contains between 10 and 100,000 retinal cells.
[0045] According to a particular embodiment of the invention, as shown in the figure 1 , the hollow three-dimensional retinal tissue unit 10 consists exclusively of: of an inner lumen 14, and of a layer of retinal pigment epithelium 12 organized around the inner lumen, the basal faces B of the retinal pigment epithelial cells being directed towards the outside of the tissue unit, and the apical faces A of the retinal pigment epithelial cells being directed towards the inner lumen.
[0046] According to another particular embodiment of the invention, as shown in the figure 2 , the hollow three-dimensional retinal tissue unit 10 consists exclusively of: of an inner lumen 14, of a layer of retinal pigment epithelium 12 organized around the inner lumen, the basal faces B of the retinal pigment epithelial cells being directed towards the outside of the tissue unit, and the apical faces A of the retinal pigment epithelial cells being directed towards the inner lumen, and of a layer of extracellular matrix 16 arranged around the layer of retinal pigment epithelium cells, at the level of the basal faces of said retinal pigment epithelium cells.
[0047] The different differentiated cells constituting the tissue unit according to the invention, whatever the embodiment, may possibly have been obtained from pluripotent stem cells, in particular human pluripotent stem cells, or possibly have been directly reprogrammed from adult cells such as fibroblasts or peripheral blood mononuclear cells for example.
[0048] The tissue unit according to the invention can be in any three-dimensional form, that is to say it can have the shape of any object in space. Preferably, the tissue unit according to the invention is in the form of a hollow ovoid, a hollow cylinder, a hollow spheroid or a hollow sphere. It is the external layer of the tissue unit, that is to say the retinal pigment epithelium layer or the extracellular matrix layer when present, which gives its size and shape to the tissue unit according to the invention. Preferably, the largest dimension of the tissue unit according to the invention is less than 1 cm, even more preferably less than 0.5 cm. According to a suitable and preferred embodiment, the largest dimension of the tissue unit according to the invention is between 100 and 1000 µm. It can also be between 200 and 1000µm or between 300 and 1000µm.This dimension ensures easy implantation in the eye, particularly by injection, the largest dimension not having to be too large to be able to be implanted with a very small preliminary incision. The larger the largest dimension, the larger the incision made in the eye must be and it is important to limit the size of the incision as much as possible to limit the risks and the impact on the patient being treated. Preferably, the smallest dimension of the tissue unit is less than 1000 µm. According to one embodiment it is between 10 and 1000 µm, preferably between 100 and 400 µm and even more preferably between 200 and 300 µm.This smaller dimension is important for graft survival in vitro, particularly to promote retinal cell survival within the retinal tissue unit and to optimize reorganization and vascularization of the tissue unit after implantation in the eye.
[0049] The thickness of the retinal pigment epithelium cell layer in the tissue unit is preferably between 5 µm and 200 µm. When the tissue unit according to the invention comprises one or more other layers of retinal cells which are not retinal pigment epithelium cells, this layer or these layers together if there are several, has a thickness preferably between 20 µm and 500 µm. When an external layer of extracellular matrix is present in the tissue unit according to the invention, the thickness of this external layer of extracellular matrix is preferably between 30 nm and 500 nm.
[0050] The light preferably represents between 10% and 90% of the volume of the tissue unit according to the invention.
[0051] The retinal tissue unit according to the invention is particularly useful as a graft implantable in the eye of a human being, particularly for the treatment of retinal diseases. The shape, size and constitution of the retinal cell unit according to the invention allow the survival of the cells within the tissue unit before implantation and the successful implantation, reorganization and vascularization of the graft once implanted in the eye.
[0052] Until implantation, the tissue unit may optionally be encapsulated in a hydrogel capsule, in which it has been preferably prepared. In this case, the hydrogel capsule is preferably removed before implantation in the eye.
[0053] The tissue units according to the invention can be frozen for storage until implantation. Implementation kit
[0054] The invention also relates to a kit for implanting at least one tissue unit.
[0055] The implantation kit according to the invention comprises at least: between 1 and 10,000 tissue units according to the invention, the tissue units possibly being encapsulated in a hydrogel capsule, possibly means for removing the hydrogel capsule, in the case where the capsule units are encapsulated in a hydrogel capsule, a surgical implantation device capable of implanting said tissue unit(s) in a human eye.
[0056] The means for removing the hydrogel capsule must allow the capsule to be removed by hydrolysis, dissolution, piercing and / or rupture by any biocompatible means, i.e. non-toxic to the cells. Preferably, the means of removal are chosen from buffer solutions (such as, for example, phosphate buffered saline, also called PBS for “phosphate buffered saline”), a buffer containing a divalent ion chelator (such as, for example, EDTA), enzymes capable of lysing the hydrogel (to be chosen according to the nature of the hydrogel).
[0057] The surgical implantation device may be a needle or a cannula whose internal diameter allows the passage of the tissue units according to the invention to be grafted, preferably between 100µm and 1mm and whose external diameter is not too traumatic for the structure of the treated eye, preferably less than 2mm.
[0058] The number of tissue units according to the invention present in the device is between 1 and 10,000, preferably between 10 and 1,000. This number varies depending on the retinal disease to be treated and the size of the area of the retina which is no longer functional.
[0059] In the implantation kit, the tissue units may be outside the implantation device and / or already introduced in whole or in part into the surgical implantation device.
[0060] The tissue units according to the invention present in the kit can be frozen outside the device and / or frozen in the surgical implantation device. In this case, the tissue units according to the invention must be thawed before use by any suitable means allowing all the properties of the tissue units to be preserved. This may include standard cell biology protocols using DMSO, as antifreeze, or those applied for the freezing of in vitro fertilization embryos using sugars such as sucrose and alcohols such as ethylene glycol.
[0061] If the tissue units were frozen encapsulated in a hydrogel capsule, the encapsulated tissue units should first be thawed and then the hydrogel capsules removed. Preparation process
[0062] The invention also relates to a method for preparing a tissue unit according to the invention. In particular, the method consists of producing at least one tissue unit according to the invention, by producing cellular microcompartments comprising a hydrogel capsule surrounding: differentiated retinal pigment epithelium cells and possibly other differentiated retinal cells, or stem cells or progenitor cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, or differentiated cells intended to undergo in the capsule: * either trans-differentiation into retinal cells, at least into retinal pigment epithelium cells, * or reprogramming in the capsule so that they become induced pluripotent stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells.
[0063] The capsule is then preferentially removed to allow the cells of the tissue unit to implant in the retina after transplantation into the eye.
[0064] The method for preparing a tissue unit according to the invention comprises at least the implementation of the steps which consist of: produce a cellular microcompartment comprising, inside a hydrogel capsule: * preferably at least elements of the extracellular matrix, secreted by the cells or provided by the operator, preferably at least a portion of the extracellular matrix is provided in addition to the extracellular matrix naturally secreted by the cells, * cells capable of differentiating at least into retinal pigment epithelium cells, or at least differentiated retinal pigment epithelium cells, the cells capable of differentiating at least into retinal pigment epithelium cells being chosen from: * stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, * progenitor cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells,* differentiated cells capable of undergoing trans-differentiation into retinal cells, at least into retinal pigment epithelium cells, * differentiated cells capable of undergoing reprogramming so that they become induced pluripotent stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells if the cells introduced into the microcompartment are cells capable of differentiating into at least retinal pigment epithelium cells: inducing cell differentiation within the cell microcompartment, so as to obtain at least retinal pigment epithelium cells and possibly other retinal cells, removing the hydrogel capsules, by hydrolysis, dissolution, piercing and / or rupture,to recover the retinal pigment epithelium cells and any other retinal cells in the form of a hollow three-dimensional retinal tissue unit comprising, organized around an internal lumen, at least one layer of retinal pigment epithelium of which the basal face of each retinal pigment epithelium cell is positioned towards the outside and the apical face towards the lumen.
[0065] Advantageously, the total or partial encapsulation in the hydrogel and the provision of extracellular matrix combined, is a suitable means to allow the polarization of the cells of the retinal pigment epithelium. Indeed, the polarization of said cells can be obtained by deposition of a layer of matrix on the internal face of the hydrogel capsules which positions the basal face of the cells, the tissue organizes itself around the light following this indication of polarity (as illustrated in the Figure 9which shows that a layer of extracellular matrix anchored to the alginate shell induces cell polarization as evidenced by the flattening of tissues against the alginate due to the high tensile strength of the gel dictating the shape of the tissue). Preferably, the hydrogel used is biocompatible, i.e., it is not toxic to the cells. The hydrogel capsule must allow the diffusion of oxygen and nutrients to feed the cells contained in the microcompartment and allow their survival. According to one embodiment, the capsule comprises alginate. It may consist exclusively of alginate. The alginate may in particular be a sodium alginate, composed of 80% α-L-guluronate and 20% β-D-mannuronate, with an average molecular mass of 100 to 400 kDa and a total concentration of between 0.5 and 5% by mass.
[0066] The hydrogel capsule makes it possible to protect the cells from the external environment, to limit the uncontrolled proliferation of the cells, and their controlled differentiation into retinal cells, at least into retinal pigment epithelium cells. A capsule very preferably surrounds a single tissue unit according to the invention and each tissue unit is surrounded by a single hydrogel capsule.
[0067] Once the retinal tissue unit according to the invention is obtained, i.e. when the cells are differentiated into retinal cells including at least one layer of retinal pigment epithelium cells, and the shape and size are those desired, the capsule is removed. The removal of the capsule can be carried out at the end of the process or later in time before implantation in the eye. The removal of the capsule can be carried out by hydrolysis, dissolution, piercing and / or rupture by any biocompatible means, i.e. non-toxic to the cells. For example, the removal can be carried out using phosphate buffered saline, a divalent ion chelator, an enzyme such as alginate lyase if the hydrogel comprises alginate and / or laser microdissection. Since the elimination of the hydrogel is total, the tissue unit according to the invention is free of hydrogel when it is implanted in the eye.
[0068] Any method for producing cellular microcompartments containing, inside a hydrogel capsule, at least retinal pigment epithelium cells or cells capable of giving rise to at least retinal pigment epithelium cells and optionally extracellular matrix and / or retinal cells other than retinal pigment epithelium cells or cells capable of giving rise to at least retinal cells other than retinal pigment epithelium cells, may be used. A suitable method is described in particular in application WO2018 / 096277. In a particular embodiment, the step of producing a cellular microcompartment of the preparation method according to the invention comprises the steps consisting of: incubate pluripotent stem cells in a culture medium, preferably a culture medium based on DMEM or DMEM-F12, FGF-2 or a molecule reproducing its action on the cell, TGF-beta or a molecule reproducing its action on the cell. mix the pluripotent stem cells with an extracellular matrix, encapsulate the mixture in a hydrogel layer.
[0069] The encapsulated cells for the preparation of tissue units according to the invention are preferably chosen from: cells capable of differentiating into at least retinal pigment epithelium cells, these cells being: * either stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, preferably embryonic stem cells or induced pluripotent stem cells, very preferably induced pluripotent stem cells, and / or, * either progenitor cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, and / or differentiated retinal pigment epithelium cells and possibly differentiated retinal cells other than retinal pigment epithelium cells, and / or differentiated cells capable of undergoing trans-differentiation into retinal cells, at least into retinal pigment epithelium cells,and / or differentiated cells capable of undergoing reprogramming so that they become induced pluripotent stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells.
[0070] The encapsulated cells may be immunocompatible with the person intended to receive the tissue unit, to avoid any risk of rejection. In one embodiment, the encapsulated cells have been previously collected from the person in whom the tissue unit(s) are to be implanted.
[0071] Differentiation into retinal pigment epithelium cells can be achieved by any suitable method. This may include a known method such as one described in Leach et al. (“Concise Review: Making Stem Cells Retinal: Methods for Deriving Retinal Pigment Epithelium and Implications for Patients With Ocular Disease,” Stem Cells 2015;33:2363-2373). The basal medium can be DMEM (“Dulbecco's modified Eagle's medium”) or DMEMF12, which can be supplemented with KSR-XF (“KnockOut DMEM medium”) or N-2 and / or B27, 1% GlutaMax, and 1% nonessential amino acid solution. Induction can also be achieved with the sequence as published in Choudhary et al. (“Directing Differentiation of Pluripotent Stem Cells Toward Retinal Pigment Epithelium Lineage” STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1-12)
[0072] Differentiation into retinal cells other than retinal pigment epithelium cells can be achieved by any suitable method. This may include a known method such as the method described in Barnea-Cramer et al. (“Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice” Nature, Scientific Reports, published July 13, 2016). Differentiation can therefore be achieved with DMEMF12, which can be supplemented with KSR-XF (KnockOut DMEM medium) or N-2 and / or B27, 1% GlutaMax, and 1% non-essential amino acid solution.
[0073] In a particular embodiment, the step of inducing cell differentiation of the preparation method according to the invention comprises the steps consisting of: cultivate the microcompartment in a pluripotent cell culture medium until at least 10 cells are obtained, preferably 100 cells, cultivate the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and LDN193189 and SB431542 and 20 µg / ml human insulin, cultivate the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and LDN193189 and SB431542, cultivate the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and 10 ng / ml of human BDNF, 10 ng / ml of human CNTF, 2 µM of retinoic acid and 10 µM of DAPT. Preferably the microcompartments are cultured for at least 18 days, preferably between 18 and 50 days.
[0074] In one embodiment of a tissue unit comprising a layer of retinal pigment epithelium and at least one layer of other retinal cells, the method comprises co-encapsulating retinal pigment epithelium cells and the other cells. Preferably, the cells from a few days of each differentiation are co-encapsulated to form a structure containing one of retinal pigment epithelium and one of neural retina. The cells are then matured in the capsule for 5 to 50 days, more preferably 10 to 25 days before obtaining a tissue unit according to the invention.
[0075] Light is generated at the time of formation of the three-dimensional tissue unit, by the cells multiplying and developing. The light may contain a liquid and in particular the culture medium used for the implementation of the process.
[0076] The method according to the invention may comprise a step of amplifying the retinal pigment epithelium cells in the microcompartment.
[0077] An embodiment of a microcompartment 20 comprising a hollow three-dimensional retinal tissue unit 10 according to the invention is shown in the figure 3 . In this embodiment, the microcompartment is made up exclusively of: of a hydrogel layer 22, and of a tissue unit 10, consisting of: * an internal lumen 14, * a layer of retinal pigment epithelium 12 organized around the internal lumen, the basal faces B of the retinal pigment epithelial cells being directed towards the outside of the tissue unit, and the apical faces A of the retinal pigment epithelial cells being directed towards the internal lumen, * a layer of extracellular matrix 16 arranged around the layer of retinal pigment epithelium cells, at the level of the basal faces of said retinal pigment epithelium cells.
[0078] Another embodiment of a microcompartment 20 comprising a hollow three-dimensional retinal tissue unit 10 according to the invention is shown in the figure 4 . In this embodiment, the microcompartment is made up exclusively of: of a hydrogel layer 22, and of a tissue unit 10, consisting of: * an inner lumen 14, * a layer 18 of retinal cells other than retinal pigment epithelial cells, preferably a layer of neural retina, * a layer of retinal pigment epithelium 12 organized around the inner lumen, the basal faces B of the retinal pigment epithelial cells being directed towards the outside of the tissue unit, and the apical faces A of the retinal pigment epithelial cells being directed towards the inner lumen, * a layer of extracellular matrix 16 arranged around the layer of retinal pigment epithelium cells, at the level of the basal faces of said retinal pigment epithelium cells.
[0079] After the differentiation step, at any time before the implantation of the tissue units in the eye, the method according to the invention may comprise a step consisting in verifying the phenotype of the cells contained in the capsule. This verification may be carried out by identifying the expression of RPE65 by the pigment epithelium in the external position of the tissue units, in a certain embodiment and in particular for the case of tissue elements containing elements of the neural retina of recoverin in the internal position of the tissue units, light side, expressed by all the photoreceptors and rhodopsin / PDE6beta for the rods, in a certain embodiment the lumen may contain vitrosin and opticin.
[0080] The method according to the invention may comprise a step of freezing the microcompartments containing the tissue units according to the invention before removing the hydrogel layer or of freezing the tissue units after the step of removing the hydrogel capsule. The freezing is preferably carried out at a temperature between -190°C and -80°C.
[0081] The microcompartments containing the tissue units according to the invention before removal of the hydrogel layer or the tissue units after the step of removing the hydrogel capsule, can be stored under the following conditions between +4°C and room temperature. The tissue units according to the invention can also be used directly after carrying out the method according to the invention, without storage.
[0082] The preparation method according to the invention, before or after possible thawing of the microcompartments containing the tissue units before removal of the hydrogel layer or the tissue units, may also comprise an additional step consisting of loading a surgical implantation device with at least one tissue unit according to the invention, preferably between 10 and 1000 tissue units, even more preferably between 10 and 100 tissue units. Implantation of tissue units into the eye
[0083] The hollow three-dimensional tissue unit, comprising, organized around an internal lumen, at least one layer of retinal pigment epithelium cells of which the basal face of each retinal pigment epithelium cell is positioned outward and the apical face towards the internal lumen, can be used in the treatment of a retinal disease, in particular in a patient in need thereof. Treatment means preventive, curative or symptomatic treatment, i.e. any act intended to improve the sight of a person temporarily or permanently, and preferably also to eradicate the disease and / or stop or delay the progression of the disease and / or promote the regression of the disease.
[0084] Indeed, the tissue units according to the invention can be used for the treatment of retinal diseases in humans, in particular degenerative diseases of the retina, and preferably a disease chosen from age-related macular degeneration, diabetic retinopathy, retinopathies linked to trauma to the eye and hereditary retinopathies.
[0085] The treatment consists of implanting, grafting the tissue units according to the invention into the eye, at the level of the retina, and in particular at the level of the Bruch membrane, that is to say between the Bruch membrane and the neural retina. A surgical implantation device suitable for implantation in the eye is very preferably used. This may include needles, cannulas or other devices for depositing the tissue units, such as those used for implanting stents in the arteries or surgical micro-implants. The implantation may be carried out in particular by implementing the steps consisting of: penetrating or incising the retina with the surgical implantation device in the treatment area, injecting the tissue units under the retina, preferentially at the level of Bruch's membrane, i.e. between Bruch's membrane and the neural retina, removing the surgical implantation device while preventing the cells from flowing back into the vitreous body.
[0086] In one embodiment, during a single implantation, between 1 and 10,000 units of tissue according to the invention are implanted.
[0087] If necessary, it is possible to perform several simultaneous or successive implantations in different areas of the retina, preferably at the level of Bruch's membrane, in particular in the case where several separate areas are affected by the disease or if the area on which the graft is to be performed is too large to perform a graft in only one place.
[0088] Similarly, in the same area, if a single graft is not enough, several implantations can be carried out again in the same area, within a more or less significant period of time.
[0089] The implantation of tissue units according to the invention allows patients suffering from retinal diseases, and in particular degenerative diseases of the retina, to at least partially regain their sight.
[0090] The invention is now illustrated by results shown on the Figures 5 to 8 .
[0091] The retinal epithelium tissues illustrated in these different figures were obtained by implementing a method comprising the steps of: produce a cellular microcompartment comprising, inside a hydrogel capsule: * elements of the extracellular matrix provided by the operator, * pigmented retinal epithelium cells,
[0092] These pigmented retinal epithelium cells can be obtained in the following way: cultivate stem cells induced to pluripotency in i) a petri dish until colonies containing several dozen cells are obtained ii) the microcompartment in a culture medium for pluripotent cells, until at least 10 cells are obtained in the microcompartment, preferably 100 cells, cultivate: i) the colonies ii) the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and LDN193189 and SB431542 and 20 µg / ml human insulin, cultivate: i) the colonies ii) the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and LDN193189 and SB431542, cultivate: i) the colonies ii) the microcompartment in a DMEMF12 culture medium supplemented with N-2 and B27, 1% GlutaMax, and 1% non-essential amino acid solution and 10 ng / ml of human BDNF, 10 ng / ml of human CNTF,2 µM retinoic acid and 10 µM DAPT. ,
[0093] On the Figure 5 , the capsule obtained by encapsulation of pigmented epithelial cells of the retina resulting from the differentiation of induced cells proliferated within the microcompartment to organize itself in the form of a polarized tissue unit. On the Figure 5 we clearly see the formation of a mature monostratified pigmented squamous epithelium (black arrow) (typically enabled by the formation of tight junctions white arrow) typical of the tissue structure of pigmented epithelial cells of the retina in vivo.
[0094] On the figure 6, the capsules obtained by encapsulation of pigmented epithelial cells of the retina resulting from the differentiation of cells induced to pluripotency show the structure in pigmented epithelial sheet whatever the number of cells in the tissue (of the order of a hundred cells on the left, size: 50µm, insert A, and of the order of a thousand cells on the right, size: 250µm, insert B) typical of the tissue structure of pigmented epithelial cells of the retina in vivo. More particularly we see on the figure 6that the cells are organized into a hollow spheroid (insert B) or hollow ovoid (insert E) according to an apico-basal polarization characterized in that the apical face is positioned towards the inside of the tissue unit and the basal face towards the outside of the tissue unit located here in contact with the alginate layer. In particular, the intracellular pigments are located on the apical face of the cells (insert D, transmitted light, white arrow) with a basal organization of the nuclei (insert B, DAPI, white arrow) corresponding to the topology encountered in vivo.
[0095] On the figure 7 Capsules obtained by encapsulation of pigmented epithelial cells of the retina from the differentiation of cells induced to pluripotency, were amplified by 10 in 4 weeks ( Figures 7a and 7b ) and 4 times in 4 weeks ( Figures 7c and 7d ). These figures illustrate that the retinal tissue units according to the invention can have variable cell densities.
[0096] Finally, on the sequential images of the figure 8 , several retinal tissue units according to the invention (without hydrogel capsule) were placed on a substrate simulating the extracellular matrix of the back of the eye (here matrigel simulating Brusch's membrane). It can be seen that the retinal tissue units (black arrows) are capable, thanks to the positioning of their basal face on the outer side, of attaching to the substrate simulating the extracellular matrix of the back of the eye by emitting cells adherent to the substrate (white arrows) which migrate (grey arrows) to cover the substrate and form a monolayer (bottom right insert corresponding to 122 hours of culture).
Claims
1. A hollow three-dimensional retinal tissue unit comprising, organized around an inner cavity, at least one layer of differentiated living human retinal pigment epithelium cells, with the basal side of each retinal pigment epithelium cell pointing outwards and the apical side pointing toward the inner cavity.
2. The retinal tissue unit according to claim 1, characterized in that it also comprises an outer layer of extracellular matrix located on the basal side of the retinal pigment epithelium cells.
3. The retinal tissue unit according to one of the preceding claims, characterized in that it is in the form of a hollow ovoid, a hollow cylinder, a hollow spheroid or a hollow sphere.
4. The retinal tissue unit according to the preceding claim, characterized in that its largest dimension is between 100 and 1000 µm.
5. The retinal tissue unit according to the preceding claim, characterized in that its smallest dimension is between 10 and 1000 µm.
6. The retinal tissue unit according to one of the preceding claims, characterized in that the juxtaposed retinal pigment epithelium cells are connected to one another on their lateral sides by tight junctions.
7. The retinal tissue unit according to one of the preceding claims, characterized in that it also comprises, at the apical side of the retinal pigment epithelium cells, organized around the inner cavity, at least one layer of differentiated living human retinal cells other than retinal pigment epithelium cells.
8. The retinal tissue unit according to the preceding claim, characterized in that differentiated living human retinal cells other than retinal pigment epithelium cells are selected from rods, cones, ganglion cells, amacrine cells, bipolar cells and horizontal cells.
9. The retinal tissue unit according to one of the preceding claims, characterized in that it contains from 10 to 100,000 retinal cells.
10. The retinal tissue unit according to one of the preceding claims, characterized in that the retinal pigment epithelium cells and / or any other retinal cells have been obtained from induced pluripotent stem cells (IPS).
11. The retinal tissue unit according to one of the preceding claims, characterized in that it is encapsulated in a hydrogel capsule.
12. A method for preparing a retinal tissue unit according to one of claims 1 to 11, comprising the steps of: - producing a cellular microcompartment comprising, inside a hydrogel capsule: * optionally at least extracellular matrix elements, secreted by the cells or added, * cells capable of differentiating into at least retinal pigment epithelium cells, or at least differentiated retinal pigment epithelium cells, the cells capable of differentiating into at least retinal pigment epithelium cells being selected from: * stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, * progenitor cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells, * differentiated cells capable of undergoing trans-differentiation into retinal cells, at least into retinal pigment epithelium cells, * differentiated cells capable of undergoing reprogramming so that they become induced pluripotent stem cells capable of differentiating into retinal cells, at least into retinal pigment epithelium cells - if the cells introduced into the microcompartment are cells capable of differentiating into at least retinal pigment epithelium cells: inducing cell differentiation within the cell microcompartment, so as to obtain at least retinal pigment epithelium cells and optionally other retinal cells, - removing hydrogel capsules by hydrolysis, dissolution, piercing and / or rupture to recover retinal pigment epithelium cells and any other retinal cells in the form of a hollow, three-dimensional retinal tissue unit,13. The method according to the preceding claim, characterized in that it comprises a step of amplifying the retinal pigment epithelium cells14. The method according to one of claims 12 or 13, characterized in that the cells capable of differentiating at least into retinal pigment epithelium cells are pluripotent stem cells.
15. The method according to the preceding claim, characterized in that the pluripotent stem cells are induced pluripotent stem cells (IPS).
16. The method of preparing a retinal tissue unit according to one of claims 12 to 15, characterized in that it comprises a further step of loading a surgical implantation device suitable for injection into the eye with said tissue unit.
17. A kit for implanting tissue units according to one of claims 1 to 11 into the eye, characterized in that it comprises: - between 1 and 10,000 tissue units according to one of claims 1 to 11, - a surgical implantation device suitable for implanting said tissue unit(s) into a human eye.
18. The kit for implanting tissue units into the eye according to claim 17, characterized in that it comprises: - between 1 and 10,000 tissue units according to claim 11, - hydrogel capsule removal means, - a surgical implantation device suitable for implanting said tissue unit(s) into a human eye.
